Dog (normal-sighted and RPE65-mutant Briard) and non-human primate
“Single dose and repeat dose toxicology studies were conducted in normal-sighted dogs, RPE65 mutant dogs, and normal-sighted non-human primates (NHPs).”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Why that species
RPE65-/- Briard dog is a natural large-animal disease model; eye size makes dog more relevant than mouse
“The applicant noted that relative transduction efficiency of AAV2 in RPE cells across species is not known but that, given the sizes of eye in dog and mouse, the studies in Briard dogs are more relevant to human effects than those in mice”
Yes: precursor vector AAV2-hRPE65v1 (low RPE65 expression) used in GLP dog studies; clinical vector in NHP and re-dosing studies
“Thus, any potential toxicity due to the RPE65 protein cannot be adequately assessed using this vector construct.”
✓ VerifiedFDA pharmacology/toxicology review, p. 27Source ↗
Species: general tox
Dog (normal-sighted and RPE65-mutant) and non-human primate
“Single dose and repeat dose toxicology studies were conducted in normal-sighted dogs, RPE65 mutant dogs, and normal-sighted non-human primates (NHPs).”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Species: DART
Not conducted
“Animal reproductive studies have not been conducted with LUXTURNA.”
Yes: early dog efficacy studies used a vector encoding canine RPE65; later studies used the human RPE65 vector
“In some of the early studies in dogs, the virus used encoded for canine RPE65 and not human RPE65; however, latterly, virus encoding human RPE65 (hRPE65) was also used in mice and dogs.”